- Home
- TMHC vs GRFS Comparison
TMHC vs GRFS Comparison
Compare TMHC & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMHC | GRFS |
|---|---|---|
| Founded | 1936 | 1940 |
| Country | United States | Spain |
| Employees | N/A | 25247 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.0B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TMHC | GRFS |
|---|---|---|
| Price | $71.86 | $7.16 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $71.71 | $10.15 |
| AVG Volume (30 Days) | ★ 4.0M | 657.9K |
| Earning Date | 04-22-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $4,762,059,000.00 | N/A |
| Revenue This Year | N/A | $4.49 |
| Revenue Next Year | $8.96 | $6.42 |
| P/E Ratio | $71.15 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.15 | $6.96 |
| 52 Week High | $72.27 | $11.14 |
Technical Indicators
Market Signals| Indicator | TMHC | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 73.35 | 38.73 |
| Support Level | $59.99 | N/A |
| Resistance Level | $72.26 | $7.73 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | -0.44 | -0.01 |
| Stochastic Oscillator | 43.26 | 25.97 |
Price Performance
Historical ComparisonAbout TMHC Taylor Morrison Home Corporation
Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.